BRAF and colonic neoplasm: When also MMR-status was considered (56% overlap between dMMR and BRAF-V600Emt), the differences became even more marked (RAS&BRAFwt/pMMR in 18% vs 41% vs 30%, p < 0.001), i.e., only a fraction of right colon tumours belong to a “treatment-sensitive group”.